A strong educational programme will also provide the next generation of experts with the necessary background and expertise to though maintain this leading position, and integrate the voices of patient organisations in the development of future research plans. Cutting edge treatments currently under development for muscular dystrophies and spinal muscular atrophy have been specifically targeted in this process, while Inhibitors,research,lifescience,medical future developments for other disease groups have been benefiting from the durable infrastructure of the TNCC, which will act as

the portal for future pharmaceutical developments in the neuromuscular field. Table 1 TREAT-NMD partners. Knowledge of disease causing genes has begun to allow the elucidation of the molecular pathological mechanisms underlying NMDs, leading to plans for

specific gene based therapies or targeted pharmaceutical approaches. Inhibitors,research,lifescience,medical Some of these treatment options are beginning to move to human studies. Examples include antisense oligonucleotide treatment and stop codon suppression for Duchenne Muscular Dystrophy (DMD), myostatin inhibition in a range of muscular dystrophies, gene therapy approaches to DMD and pharmacological approaches to survival motor neuron gene (SMN) upregulation in Spinal Muscular Atrophy (SMA). These developments, while universally welcomed Inhibitors,research,lifescience,medical amongst scientists, clinicians and patient organisations, have exposed the lack of harmonisation of approaches to possibly beneficial therapeutics in NMD, which is hindering a smooth move into clinical trials. TREAT-NMD is addressing this lack of harmonisation by creating a Inhibitors,research,lifescience,medical model in which the development of the tools of the Network through a long-term vision will bring delivery of new treatments while supporting optimal

care for patients. The components of the TREAT-NMD model are illustrated in Figure ​Figure1.1. Individual partners (Table ​(Table1),1), working with international collaborators, are responsible for the delivery of each of these components of the network which address Inhibitors,research,lifescience,medical specific bottlenecks in therapy development and delivery including: Figure 1 The TREAT-NMD network has worked to develop tools for trial readiness in a number of areas, and is also collaborating on additional research projects in the field. Cilengitide the time taken for proper protocol design and lack of generally accepted outcome measures addressed via consensus meetings (1), regulatory engagement and a publicly http://www.selleckchem.com/products/dorsomorphin-2hcl.html available registry of outcome measures available through the TREAT-NMD website; lack of a number of appropriately trained sites with similar levels of standards of care and appropriate staff to run trials addressed via the establishment of the trial site registry; lack of knowledge about patient availability and characteristics addressed via the patient registries; better understanding of the interpretation of animal model experiments and prioritisation of drug candidates addressed by establishing an expert group to evaluate promising drug targets.